You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: November 2, 2024

SCHERING Company Profile

✉ Email this page to a colleague

« Back to Dashboard

What is the competitive landscape for SCHERING, and what generic and branded alternatives to SCHERING drugs are available?

SCHERING has one hundred and one approved drugs.

Summary for SCHERING

US Patents:	0
Tradenames:	63
Ingredients:	55
NDAs:	101

Drugs and US Patents for SCHERING

+ Get email alerts for changes to this table

Subscribe to access the full database, or Sign Up
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Schering	RENORMAX	spirapril hydrochloride	TABLET;ORAL	020240-001	Dec 29, 1994		DISCN	No	No		⤷ Sign Up				⤷ Sign Up
Schering	CHLOR-TRIMETON	chlorpheniramine maleate	TABLET;ORAL	006921-002	Approved Prior to Jan 1, 1982		DISCN	No	No		⤷ Sign Up				⤷ Sign Up
Schering Plough	IMDUR	isosorbide mononitrate	TABLET, EXTENDED RELEASE;ORAL	020225-002	Aug 12, 1993		DISCN	Yes	No		⤷ Sign Up				⤷ Sign Up
Schering	TREMIN	trihexyphenidyl hydrochloride	TABLET;ORAL	080381-001	Approved Prior to Jan 1, 1982		DISCN	No	No		⤷ Sign Up				⤷ Sign Up
Schering	DIPROLENE	betamethasone dipropionate	CREAM, AUGMENTED;TOPICAL	019408-001	Jan 31, 1986		DISCN	No	No		⤷ Sign Up				⤷ Sign Up
Schering	CELESTONE	betamethasone	CREAM;TOPICAL	014762-001	Approved Prior to Jan 1, 1982		DISCN	No	No		⤷ Sign Up				⤷ Sign Up
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

Expired US Patents for SCHERING

Subscribe to access the full database, or Sign Up
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Schering	NOXAFIL	posaconazole	SUSPENSION;ORAL	022003-001	Sep 15, 2006	5,661,151	⤷ Sign Up
Schering	VANCERIL	beclomethasone dipropionate	AEROSOL, METERED;INHALATION	017573-001	Approved Prior to Jan 1, 1982	4,364,923	⤷ Sign Up
Schering	REBETOL	ribavirin	SOLUTION;ORAL	021546-001	Jul 29, 2003	6,461,605*PED	⤷ Sign Up
Schering	NORMODYNE	labetalol hydrochloride	TABLET;ORAL	018687-003	Aug 1, 1984	4,012,444	⤷ Sign Up
Schering	REBETOL	ribavirin	SOLUTION;ORAL	021546-001	Jul 29, 2003	6,172,046*PED	⤷ Sign Up
Schering	NORMOZIDE	hydrochlorothiazide; labetalol hydrochloride	TABLET;ORAL	019046-001	Apr 6, 1987	4,066,755	⤷ Sign Up
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>Patent No.	>Patent Expiration

Paragraph IV (Patent) Challenges for SCHERING drugs

Drugname	Dosage	Strength	Tradename	Submissiondate
➤ Subscribe	Oral Suspension	40 mg/mL	➤ Subscribe	2011-02-28
➤ Subscribe	Injection	18 mg/mL, 16.7 mL vials	➤ Subscribe	2015-11-24
➤ Subscribe	Delayed-release Tablets	100 mg	➤ Subscribe	2014-06-16

Similar Applicant Names

Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.